|
International Myeloma Working Group
|
|
International Myeloma Working Group The International Myeloma Working Group (IMWG) was established by the International Myeloma Foundation to provide a forum for researchers to collaborate on cllinical and scientific issues deemed important to the scientific and clinical communities. 134 researchers from around the world are involved with the group. The group's work to date has focused on myeloma treatments and diagnostic systems. Participation in the group is on a volunteer basis and membership is open to credentialed researchers and clinicians working in multiple myeloma. Mission To conduct basic, clinical and translational research in a collaborative manner to improve outcomes in myeloma, and to provide scientifically valid and critically appraised consensus opinions on the diagnosis and treatment of myeloma and related disorders. Projects The IMWG undertakes projects with the objective of publishing in peer-reviewed journals scientific findings and consensus statements in areas where there is currently no standard of care. A list of completed projects is listed below. * Myeloma Management Guidelines * International Staging System for Multiple Myeloma * Molecular classification of multiple myeloma * International uniform treatment response criteria for multiple myeloma * Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders * Use of Bisphosphonates in Multiple Myeloma * The use of biochemical markers of bone remodeling in multiple myeloma * Consensus statement on stem cell collection and high-dose therapy for multiple myeloma * Consensus perspectives on stem cell mobilization following initial therapy with thalidomide, lenalidomide or bortezomib * Guidelines for treating myeloma patients not eligible for stem cell transplant * Consensus statement and guidelines for imaging in multiple myeloma * Guidelines for serum-free light chain analysis in multiple myeloma * Consensus statement on vertebral augmentation (vertebroplasty and kyphoplasty) in the treatment of multiple myeloma * Myeloma in patients younger than 50 presents with more favorable features * Utility of the International Staging System for Brazilian patients * Prevention of thalidomide-associated deep vein thrombosis in multiple myeloma patients See Also
|
| < Prev | Next > |
|---|
Main Menu
| Home |
| Articles |
| Search |
| Submit Article |
| Contact Us |
| Donate to Wikibin |
